The particulars: a 31G needle · semaglutide · 3.33 mg/mL.
I am trying to choose between two options that are usually discussed as though only one exists.
I am not optimising for price, but I am not indifferent to it either.
So which one, and on what grounds?
At 3.33 mg/mL a 1 mg dose is 0.3 mL — 30 units on a U-100 barrel — and no needle gauge changes that number. Gauge changes three other things: how long the draw takes, how much stays behind in the hub, and how much rubber you core out of the stopper. On the 31G scale a larger number is a finer needle, so a 31G needle is fine enough that a viscous solution draws slowly and a hurried draw pulls bubbles. If you are drawing 30 units at a time, the dead space matters more than the bore: a fixed-needle barrel loses microlitres, a luer hub loses tens of them, and at 3.33 mg/mL each microlitre is 3.33 µg.
The short version: 21G to 23G to draw, 29G to 31G to inject, and never the same needle for both.
For injecting, 29G to 31G is the usual range and the difference in perceived discomfort between them is small. Needle length matters more than gauge for comfort at these volumes.
Drawing a viscous or foamy solution through a fine needle takes long enough that people rush the plunger, which causes more foaming. Using a wider drawing needle is the fix.
The Hagen–Poiseuille relation gives flow proportional to the fourth power of radius, which is the quantitative basis for every gauge recommendation here.
Length affects comfort more than gauge does at these volumes.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsCoring the stopper with a large-bore needle is the risk at the drawing end, and it is real.
Flow through a needle scales with the fourth power of the internal radius under the Hagen–Poiseuille relation. Halving the radius reduces flow sixteen-fold at the same pressure, which is why a 31G needle draws so much more slowly than a 21G.
Specifically, fixed-needle insulin syringes are supplied in 29G to 31G and cannot be swapped for drawing, which is the trade-off against their much lower dead space.
Coring risk as a function of needle gauge and insertion technique is documented in pharmacy compounding guidance.
Angle the bevel and insert gently to avoid coring the stopper.
edited 19 Oct 2024 by h_pergande — added a caveat about sampling
Answer first: use the largest bore you tolerate for drawing and the smallest for injecting, because the two operations have opposite requirements.
Stopper coring — punching a disc of rubber into the solution — is a large-bore phenomenon. An 18G or 21G needle inserted straight and fast is the classic way to do it; inserting at a slight angle with the bevel up reduces the risk.
Very fine needles are more prone to bending and to blocking with any particulate, which is a practical argument for inspecting the solution before drawing.
Butyl rubber closures are specified for resealing after piercing up to a stated gauge, which is the basis for the fine-gauge repeated-entry practice.
The caveat is that no gauge choice makes a non-sterile preparation safe, and research-use compounds are not approved for human use.
Flow goes as the fourth power of radius. That is why the difference feels so large.
The honest answer is that injection gauge is a comfort decision and drawing gauge is a stopper-coring decision.
Typical outer diameters: 21G is about 0.82 mm, 23G about 0.64 mm, 25G about 0.51 mm, 29G about 0.34 mm and 31G about 0.26 mm. The gauge number and the diameter move in opposite directions.
Needle gauge to outer diameter correspondence is standardised and published; the inverse relationship between gauge number and diameter is the reason for the counter-intuitive labelling.
Higher gauge is not automatically better; it is thinner, which has costs as well as benefits.
Gauge numbers run backwards. Higher number, thinner needle.
Start with the fact that gauge numbers run backwards — a higher number is a thinner needle — which is the source of half the confusion in this tag.
A 30G or 31G needle through a butyl stopper leaves a track that reseals, which is why fine-gauge repeated entry is tolerable and coarse-gauge repeated entry is not.
The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.
Big to draw, small to inject, never the same one twice.
edited 20 Sept 2024 by sian_llewellyn — added the placebo-arm figures
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.